A Guide to the Use of Vasopressors and Inotropes for Patients in Shock
Executive Summary
Shock is a critical circulatory failure characterized by inadequate tissue perfusion and oxygenation, leading to cellular dysfunction and, if untreated, organ failure and death. The management of shock requires a sophisticated understanding of its four primary etiologies: distributive, cardiogenic, hypovolemic, and obstructive.
The primary goal of therapy is to restore hemodynamic stability and oxygen delivery. Vasopressors, which increase systemic vascular resistance (SVR), and inotropes, which enhance cardiac contractility, are the cornerstones of pharmacological intervention. Norepinephrine has emerged as the preferred first-line vasopressor for most shock states, particularly septic and cardiogenic shock, due to its efficacy and favorable safety profile compared to dopamine and epinephrine. Management strategies are increasingly guided by dynamic assessments of fluid responsiveness and etiology-specific protocols, such as the 1:1:1 transfusion ratio for hemorrhagic shock and early revascularization for cardiogenic shock.
Critical Receptor Physiology
The effectiveness of vasoactive agents is determined by their binding affinity to specific receptors:
α1-Receptors: Located in vascular smooth muscle; activation increases intracellular calcium (Ca2+), leading to vasoconstriction.
β1-Receptors: Located in the heart; activation increases heart rate (chronotropy) and contractility (inotropy).
β2-Receptors: Located in vasculature, lungs, and liver; activation leads to vasodilation (by decreasing intracellular Ca2+), bronchodilation, and increased glucose/lactate production.
V1-Receptors: Located in the vasculature; activation by vasopressin leads to potent vasoconstriction without increasing pulmonary vascular resistance.
Pathophysiology and Stages of Shock
Shock progresses through three distinct physiological stages, regardless of the underlying cause:
Compensated (Nonprogressive) Shock: The body maintains homeostasis through compensatory mechanisms. The sympathetic nervous system (SNS) is activated, releasing epinephrine and norepinephrine to increase cardiac output and SVR. The Renin-Angiotensin-Aldosterone System (RAAS) is triggered by decreased renal blood flow, promoting further vasoconstriction and fluid retention.
Uncompensated (Progressive) Shock: Compensatory mechanisms fail to meet oxygen demand. Capillary permeability alters, leading to fluid leakage into the interstitial space, which decreases circulating volume and exacerbates hypoperfusion.
Irreversible (Refractory) Shock: This final stage is characterized by profound peripheral vasoconstriction, decreased cardiac output, and severe anaerobic metabolism. Lactic acid accumulation causes capillary dilation and pooling, leading to cerebral ischemia and circulatory collapse. At this stage, therapeutic interventions are generally no longer beneficial.
Clinical Management by Shock Category
1. Distributive Shock
Caused by systemic vasodilation, resulting in decreased SVR and afterload. Major types include:
Septic Shock: Defined by a Sequential Organ Failure Assessment (SOFA) score ≥ 2, the need for vasopressors to maintain a Mean Arterial Pressure (MAP) ≥ 65 mm Hg, and lactate > 2 mmol/L despite fluid resuscitation.
Management: Initial IV fluid resuscitation (30 mL/kg within 3 hours), followed by first-line norepinephrine. Vasopressin may be added as a second-line agent (0.03 units/min) if high-dose norepinephrine fails to achieve MAP goals.
Updates: The 2021 Surviving Sepsis Campaign (SSC) no longer recommends normal saline; balanced crystalloids are preferred. Prompt initiation of vasopressors, even via peripheral access, is encouraged.
Neurogenic Shock: Results from spinal cord injury (typically above T6) causing loss of sympathetic vascular tone.
Management: MAP goals of 85–90 mm Hg are recommended for the first 5–7 days post-injury to prevent secondary cord damage. Norepinephrine or dopamine are preferred for upper spinal cord injuries.
Anaphylactic Shock: Driven by a dysregulated release of vasoactive mediators like histamine.
Management: Epinephrine is the gold standard, administered intramuscularly (0.3–0.5 mg) immediately, followed by IV titration (1–10 µg/min). Glucagon is a critical adjunct for patients on beta-blockers who are unresponsive to epinephrine.
2. Cardiogenic Shock
Characterized by primary cardiac dysfunction leading to end-organ hypoperfusion, most commonly due to acute myocardial infarction.
Management: Norepinephrine is the first-line vasopressor; it is superior to dopamine in reducing mortality and causes fewer arrhythmias.
Inotropic Support: Dobutamine is the preferred first-line inotrope. Milrinone may be used, particularly in patients on beta-blockers, though it requires caution in renal dysfunction.
Definitive Care: Early revascularization is the essential therapeutic intervention.
3. Hypovolemic Shock
Resulting from loss of intravascular volume (hemorrhagic or non-hemorrhagic).
Hemorrhagic Shock: Managed through "Permissive Hypotension" (MAP goal 50–60 mm Hg) and massive transfusion protocols.
Transfusion Strategy: A 1:1:1 ratio of plasma, platelets, and red blood cells is recommended. Whole blood is increasingly utilized for its simplicity and potential mortality benefits.
Adjuncts: Tranexamic acid (TXA) should be administered early (1g bolus followed by 1g infusion) to improve survival.
Non-hemorrhagic Shock: Treated with crystalloid boluses guided by lactate clearance and urine output.
4. Obstructive Shock
Caused by physical blockages of blood flow (e.g., pulmonary embolism, tension pneumothorax, cardiac tamponade).
Management: The primary goal is clearing the obstruction. Fluids should be used cautiously, especially in pulmonary embolism, where they may worsen right ventricular distension.
Vasoactive Therapy: Norepinephrine is the first choice; vasopressin is useful in right heart failure as it does not increase pulmonary vascular resistance.
Emerging Agents
Angiotensin II (Giapreza): A synthetic peptide that induces vasoconstriction and aldosterone synthesis. It is primarily indicated for refractory distributive shock in patients with adequate cardiac output.
Levosimendan: (Not available in the US) Increases myocyte sensitivity to calcium; useful for cardiogenic shock patients on \beta-blockers.
